Takeda took a major legal charge after a federal jury in Boston found the company liable in a pay-for-delay antitrust case. The company revised fiscal year 2025 results to reflect a 402.5 billion yen provision for legal proceedings, bringing the year to an estimated 152 billion yen loss and raising the potential liability ceiling to about $2.5 billion. Takeda said it would pursue post-trial motions and an appeal while seeking a stay. The case alleged Takeda conspired with a competitor to delay generic entry of Amitiza, driving overpayments to payers and retailers. For the biotech sector, the ruling marks a high-profile legal precedent in pay-for-delay litigation involving branded drugs transitioning into generic competition—an issue that continues to influence settlement terms and lifecycle strategy.